| Autor: |
Mattei AE; EpiVax, Inc, Providence, RI, USA., Gutierrez AH; EpiVax, Inc, Providence, RI, USA., Seshadri S; EpiVax, Inc, Providence, RI, USA., Tivin J; EpiVax, Inc, Providence, RI, USA., Ardito M; EpiVax, Inc, Providence, RI, USA., Rosenberg AS; EpiVax, Inc, Providence, RI, USA., Martin WD; EpiVax, Inc, Providence, RI, USA., De Groot AS; EpiVax, Inc, Providence, RI, USA. |
| Jazyk: |
angličtina |
| Zdroj: |
MAbs [MAbs] 2024 Jan-Dec; Vol. 16 (1), pp. 2333729. Date of Electronic Publication: 2024 Mar 27. |
| DOI: |
10.1080/19420862.2024.2333729 |
| Abstrakt: |
In silico immunogenicity risk assessment has been an important step in the development path for many biologic therapeutics, including monoclonal antibodies. Even if the source of a given biologic is 'fully human', T cell epitopes that are contained in the sequences of the biologic may activate the immune system, enabling the development of anti-drug antibodies that can reduce drug efficacy and may contribute to adverse events. Computational tools that identify T cell epitopes from primary amino acid sequences have been used to assess the immunogenic potential of therapeutic candidates for several decades. To facilitate larger scale analyses and accelerate preclinical immunogenicity risk assessment, our group developed an integrated web-based platform called ISPRI, (Immunogenicity Screening and Protein Re-engineering Interface) that provides hands-on access through a secure web-based interface for scientists working in large and mid-sized biotech companies in the US, Europe, and Japan. This toolkit has evolved and now contains an array of algorithms that can be used individually and/or consecutively for immunogenicity assessment and protein engineering. Most analyses start with the advanced epitope mapping tool (EpiMatrix), then proceed to identify epitope clusters using ClustiMer, and then use a tool called JanusMatrix to define whether any of the T cell epitope clusters may generate a regulatory T cell response which may diminish or eliminate anti-drug antibody formation. Candidates can be compared to similar products on a normalized immunogenicity scale. Should modifications to the biologic sequence be an option, a tool for moderating putative immunogenicity by editing T cell epitopes out of the sequence is available (OptiMatrix). Although this perspective discusses the in-silico immunogenicity risk assessment for monoclonal antibodies, bi-specifics, multi-specifics, and antibody-drug conjugates, the analysis of additional therapeutic modalities such as enzyme replacement proteins, blood factor proteins, CAR-T, gene therapy products, and peptide drugs is also made available on the ISPRI platform. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
